<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03881774</url>
  </required_header>
  <id_info>
    <org_study_id>HenanCH CART 2-4</org_study_id>
    <nct_id>NCT03881774</nct_id>
  </id_info>
  <brief_title>Cord Blood Derived CAR-T Cells in Refractory/Relapsed B Cell Malignancies</brief_title>
  <official_title>Clinical Study of Cord Blood Derived CAR-T Cells in Patients With Refractory/Relapsed B Cell Leukemia/Lymphoma Who Are Failed for Autologous CAR-T Cells or Autologous CAR-T Can Not be Prepared</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Henan Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Henan Hualong Biotechnology Company</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Henan Cancer Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation the safety and efficacy of cord blood-derived CAR-T cells in patients with
      relapsed/refractory B cell leukemia/lymphoma whose disease relapsed after autologous CAR-T
      cells therapy or who fail to preparation for autologous CAR-T cells
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      CAR-T cells therapy is the preferred option for relapsed/refractory B cell leukemia/lymphoma.
      However, some patients will relapse after CAR-T cells therapy, and because of previous
      multicycles chemotherapy it's very difficult to abtain enough lymphocytes for preparation of
      antologous CAR-T cells. The exploration of alternative source of lymphocytes for CAR-T cells
      preparation has important clinical implications for such patients. We evaluated the efficacy
      and safety of cord blood-derived CAR-T cells in such patients, and to explore effective
      treatment options for such patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 27, 2019</start_date>
  <completion_date type="Anticipated">January 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>CAR-T cell group</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>occurrence of study related adverse events</measure>
    <time_frame>one year</time_frame>
    <description>safety of CAR-T cells</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>objective response rate</measure>
    <time_frame>three months</time_frame>
    <description>the proportion of patients with CR or PR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progression-free survival</measure>
    <time_frame>one year</time_frame>
    <description>from the date of enrollment to the first date of progression detected</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>one year</time_frame>
    <description>from the date of enrollment to the date of death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>copy number of CAR-T</measure>
    <time_frame>six months</time_frame>
    <description>copy number of CAR-T in blood and bone marrow</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Refractory</condition>
  <condition>Relapsed</condition>
  <condition>B Cell Lymphoma</condition>
  <condition>B Cell Leukemia</condition>
  <arm_group>
    <arm_group_label>experimental arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>cord blood derived CAR T cells group</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CAR-T cells</intervention_name>
    <description>collecting cord blood for CAR-T cells culture; three days later, FC regimen (fludarabine 30mg/m2/d x 3, cyclophosphamide 600-800mg/m2/d x 2) another two days later, transfusing CAR-T cell with a dose of 0.5-3x106/kg</description>
    <arm_group_label>experimental arm</arm_group_label>
    <other_name>cord blood derived CAR-T cells</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  expected lifespan ＞3 months

          -  patients with refractory/relapsed B cell leukemia/lymphoma whose diseases relapse
             after autologous CAR-T cells or the preparation for autologous CAR-T cells fails

          -  KPS ＞70

          -  for patients with lymphoma, at least one measurable lesion according to RECIST 1.1

          -  enough function of heart, liver, kidney and bone marrow

          -  no history of severy allergy

          -  no other serious diseases that conflict with this plan

          -  no other history of malignancy

          -  no serious mental illness

          -  patients and their families members agree to participate in this clinical study and
             sign the Informed Consent Form

        Exclusion Criteria:

          -  pregnant or lactating women

          -  vevere infectious or viral diseases

          -  active hepatitis B or C viral hepatitis

          -  Patients who have used large amounts of glucocorticoids or other immunosuppressive
             agents within the last 4 weeks

          -  participated in other clinical studies in the past 3 months or who have been treated
             with other gene products;

          -  others that other investigators consider not suitable for this clinical study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yongping Song, Dr.</last_name>
    <role>Study Chair</role>
    <affiliation>Henan Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yongping Song, Dr.</last_name>
    <phone>+86-37165587795</phone>
    <email>songyongping2018@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Quanli Gao, Dr.</last_name>
    <phone>+86-37165587483</phone>
    <email>gaoquanli2015@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Henan Cancer Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Quanli Gao, M.D</last_name>
      <phone>+86-15038171966</phone>
      <email>gaoquanli2015@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Lu Han, M.D</last_name>
      <phone>+86-13838583031</phone>
      <email>luhan0377@163.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Henan Cancer Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yongping Song, M.D</last_name>
      <phone>+86-37165587795</phone>
      <email>songyongping2018@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 16, 2019</study_first_submitted>
  <study_first_submitted_qc>March 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 19, 2019</study_first_posted>
  <last_update_submitted>March 19, 2019</last_update_submitted>
  <last_update_submitted_qc>March 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, B-Cell</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

